INCREASE OLE was the open-label extension of the INCREASE study (NCT02630316), which investigated the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease. We caught up with Prof. Jean Elwing (UC Health, Cincinnati, OH, USA) to discuss the methodology, inclusion criteria, and safety and tolerability findings from the INCREASE OLE study.
The abstract ‘LONG-TERM SAFETY AND TOLERABILITY OF INHALED TREPROSTINIL IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE’ was presented at CHEST 2022, 16-19 October, 2022.
Questions
- What impact has the approval of inhaled treprostinil had on the treatment paradigm for pulmonary hypertension due to interstitial lung disease? (0:16)
- What were the findings of the INCREASE study? (0:59)
- What was the methodology and inclusion criteria of the INCREASE OLE study? (2:22)
- What were the safety and tolerability findings of the study and were these consistent with the 16-week findings? (4:11)
- What will be the impact of these findings on clinical practice? (4:53)
Disclosures: Jean Elwing discloses receiving grant/ research support from Janssen, United Therapeutics, Liquidia, Phase Bio, Gossamer Bio, Bayer, Acceleron/Merck, Altavant, Aerovate, Tenax, and Pharmosa; serving on advisory boards for United Therapeutics, Altavant, Aerovate, Bayer, Gossamer Bio, Liquida, Acceleron/Merck, Janssen, and Insmed; and receiving honoraria from United Therapeutics.
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the CHEST meeting 2022.
